SCB
ALNY icon

Saudi Central Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Saudi Central Bank’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79M Buy
9,284
+4,408
+90% +$1.33M 0.04% 271
2026
Q1 		$1.61M Buy
+4,876
New +$1.66M 0.03% 236
2025
Q2 		– Sell
-51
Closed -$13.8K – 80
2025
Q1 		$13.8K Buy
+51
New +$13.1K 0.07% 249

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Saudi Central Bank's ALNY Position: Q2 2026 in Review

Saudi Central Bank increased its Alnylam Pharmaceuticals (ALNY) stake by 90% in Q2 2026, buying an estimated $1.33M and bringing the position to 9,284 shares worth $2.79M. The position accounts for 0.04% of the portfolio, ranked #271.

Saudi Central Bank first reported a position in ALNY in Q1 2025 and has held it in 3 quarters since. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Saudi Central Bank held 9,284 shares of Alnylam Pharmaceuticals worth $2.79M as of Q2 2026.
  • Saudi Central Bank bought 4,408 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.33M.
  • Alnylam Pharmaceuticals made up 0.04% of Saudi Central Bank's portfolio in Q2 2026, its #271 holding.
  • Saudi Central Bank first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Saudi Central Bank's 13F filing for Q2 2026, filed 30 Jul 2026.